Published in Neuropsychopharmacology on October 30, 2002
The dopamine hypothesis of schizophrenia: version III--the final common pathway. Schizophr Bull (2009) 6.03
The hippocampus and nucleus accumbens as potential therapeutic targets for neurosurgical intervention in schizophrenia. Stereotact Funct Neurosurg (2009) 2.24
Dopaminergic dysfunction in schizophrenia: salience attribution revisited. Schizophr Bull (2010) 1.97
Striatal presynaptic dopamine in schizophrenia, part II: meta-analysis of [(18)F/(11)C]-DOPA PET studies. Schizophr Bull (2012) 1.22
Glutamatergic dysfunction in schizophrenia: from basic neuroscience to clinical psychopharmacology. Eur Neuropsychopharmacol (2008) 1.06
The test-retest reliability of 18F-DOPA PET in assessing striatal and extrastriatal presynaptic dopaminergic function. Neuroimage (2009) 1.06
Testing models of thalamic dysfunction in schizophrenia using neuroimaging. J Neural Transm (Vienna) (2005) 1.02
Midbrain dopamine function in schizophrenia and depression: a post-mortem and positron emission tomographic imaging study. Brain (2013) 1.00
Dopamine receptors and Parkinson's disease. Int J Med Chem (2011) 0.81
Effects of dopamine D2 receptor partial agonist antipsychotic aripiprazole on dopamine synthesis in human brain measured by PET with L-[β-11C]DOPA. PLoS One (2012) 0.80
Dopamine transporter SPECT using fast kinetic ligands: 123I-FP-beta-CIT versus 99mTc-TRODAT-1. Eur J Nucl Med Mol Imaging (2004) 0.80
Poor evidence for depolarization block but uncoupling of nigral from striatal dopamine metabolism after chronic haloperidol treatment in the rat. J Neural Transm (Vienna) (2005) 0.78
Putative presynaptic dopamine dysregulation in schizophrenia is supported by molecular evidence from post-mortem human midbrain. Transl Psychiatry (2017) 0.75
Thalamic nuclear abnormalities as a contributory factor in sudden cardiac deaths among patients with schizophrenia. Clinics (Sao Paulo) (2010) 0.75
Short-term Effects of Risperidone Monotherapy on Spontaneous Brain Activity in First-episode Treatment-naïve Schizophrenia Patients: A Longitudinal fMRI Study. Sci Rep (2016) 0.75
Regulation of dopaminergic function: an [(18)F]-DOPA PET apomorphine challenge study in humans. Transl Psychiatry (2017) 0.75
Presynaptic Dopamine Capacity in Patients with Treatment Resistant Schizophrenia Taking Clozapine: An [(18)F]DOPA PET Study. Neuropsychopharmacology (2016) 0.75
Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab (2007) 11.79
Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry (2010) 3.64
Neuronal-glial glucose oxidation and glutamatergic-GABAergic function. J Cereb Blood Flow Metab (2006) 2.88
Correlation between dopamine D(2) receptors in the ventral striatum and central processing of alcohol cues and craving. Am J Psychiatry (2004) 2.84
Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol (2011) 2.84
Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy. Cell Stem Cell (2011) 2.78
Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer. Gastroenterology (2009) 2.64
Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours. Eur J Nucl Med Mol Imaging (2004) 2.45
Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer (2003) 2.37
Hepatic encephalopathy is associated with decreased cerebral oxygen metabolism and blood flow, not increased ammonia uptake. Hepatology (2013) 2.30
18F-FDG PET/CT identifies patients at risk for future vascular events in an otherwise asymptomatic cohort with neoplastic disease. J Nucl Med (2009) 2.19
Increased occupancy of dopamine receptors in human striatum during cue-elicited cocaine craving. Neuropsychopharmacology (2006) 2.15
Linear regression with spatial constraint to generate parametric images of ligand-receptor dynamic PET studies with a simplified reference tissue model. Neuroimage (2003) 2.09
Ultrastructural hippocampal and white matter alterations in mild cognitive impairment: a diffusion tensor imaging study. Dement Geriatr Cogn Disord (2004) 2.04
Color-coded diffusion-tensor-imaging of posterior cingulate fiber tracts in mild cognitive impairment. Neurobiol Aging (2005) 1.88
Sex differences in striatal dopamine release in healthy adults. Biol Psychiatry (2006) 1.87
The use of pigs in neuroscience: modeling brain disorders. Neurosci Biobehav Rev (2007) 1.86
Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol (2013) 1.84
Disturbed structural connectivity is related to inattention and impulsivity in adult attention deficit hyperactivity disorder. Eur J Neurosci (2010) 1.79
Proteome-based plasma markers of brain amyloid-β deposition in non-demented older individuals. J Alzheimers Dis (2010) 1.73
Artefactual subcortical hyperperfusion in PET studies normalized to global mean: lessons from Parkinson's disease. Neuroimage (2008) 1.72
Cross-modal plasticity revealed by electrotactile stimulation of the tongue in the congenitally blind. Brain (2005) 1.69
Using a reference tissue model with spatial constraint to quantify [11C]Pittsburgh compound B PET for early diagnosis of Alzheimer's disease. Neuroimage (2007) 1.67
Persistent cognitive and dopamine transporter deficits in abstinent methamphetamine users. Synapse (2008) 1.66
Alterations of central dopamine receptors before and after gastric bypass surgery. Obes Surg (2009) 1.65
Nigrostriatal dopamine system dysfunction and subtle motor deficits in manganese-exposed non-human primates. Exp Neurol (2006) 1.59
Real versus imagined locomotion: a [18F]-FDG PET-fMRI comparison. Neuroimage (2009) 1.56
First do no harm: managing antihistamine impairment in patients with allergic rhinitis. J Allergy Clin Immunol (2003) 1.55
18F-Fluoroethylcholine PET/CT identifies lymph node metastasis in patients with prostate-specific antigen failure after radical prostatectomy but underestimates its extent. Eur Urol (2012) 1.54
Association of low striatal dopamine d2 receptor availability with nicotine dependence similar to that seen with other drugs of abuse. Am J Psychiatry (2008) 1.53
Relationships among ventral striatal dopamine release, cortisol secretion, and subjective responses to amphetamine. Neuropsychopharmacology (2005) 1.51
11C-MCG: synthesis, uptake selectivity, and primate PET of a probe for glutamate carboxypeptidase II (NAALADase). Mol Imaging (2003) 1.49
EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2. Eur J Nucl Med Mol Imaging (2009) 1.49
Cerebrovascular brainstem diseases with isolated cranial nerve palsies. Cerebrovasc Dis (2002) 1.48
Altered effective connectivity during working memory performance in schizophrenia: a study with fMRI and structural equation modeling. Neuroimage (2003) 1.46
Quantitative MR spectroscopic imaging of brain lesions in patients with AIDS: correlation with [11C-methyl]thymidine PET and thallium-201 SPECT. Acad Radiol (2002) 1.43
Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. J Clin Psychiatry (2003) 1.41
Tc-99m sestamibi single photon emission computed tomography for guiding percutaneous coronary intervention in patients with multivessel disease: a comparison with quantitative coronary angiography and fractional flow reserve. Int J Cardiovasc Imaging (2009) 1.41
Correlation of alcohol craving with striatal dopamine synthesis capacity and D2/3 receptor availability: a combined [18F]DOPA and [18F]DMFP PET study in detoxified alcoholic patients. Am J Psychiatry (2005) 1.41
In vivo fibrillar beta-amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults. Arch Neurol (2011) 1.40
Molecular imaging of gliomas with PET: opportunities and limitations. Neuro Oncol (2011) 1.40
Capillary-oxygenation-level-dependent near-infrared spectrometry in frontal lobe of humans. J Cereb Blood Flow Metab (2006) 1.39
Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology (2002) 1.35
Longitudinal patterns of β-amyloid deposition in nondemented older adults. Arch Neurol (2011) 1.32
11C-JHU75528: a radiotracer for PET imaging of CB1 cannabinoid receptors. J Nucl Med (2006) 1.32
The role of 68Ga-DOTATATE PET/CT in suspected neuroendocrine tumors. J Nucl Med (2012) 1.31
Impairment of nigrostriatal dopamine neurotransmission by manganese is mediated by pre-synaptic mechanism(s): implications to manganese-induced parkinsonism. J Neurochem (2008) 1.31
To musicians, the message is in the meter pre-attentive neuronal responses to incongruent rhythm are left-lateralized in musicians. Neuroimage (2005) 1.30
Mechanisms of dopaminergic and serotonergic neurotransmission in Tourette syndrome: clues from an in vivo neurochemistry study with PET. Neuropsychopharmacology (2007) 1.30
COMT genotype predicts BOLD signal and noise characteristics in prefrontal circuits. Neuroimage (2006) 1.29
CNS manifestations of Fabry's disease. Lancet Neurol (2006) 1.29
Accurate event-driven motion compensation in high-resolution PET incorporating scattered and random events. IEEE Trans Med Imaging (2008) 1.29
Dopamine in amygdala gates limbic processing of aversive stimuli in humans. Nat Neurosci (2008) 1.29
Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study. Am J Psychiatry (2008) 1.27
68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. J Nucl Med (2010) 1.26
Occurence and clinical predictors of spasticity after ischemic stroke. Stroke (2010) 1.24
Imaging glial cell activation with [11C]-R-PK11195 in patients with AIDS. J Neurovirol (2005) 1.23
Elevated intrasynaptic dopamine release in Tourette's syndrome measured by PET. Am J Psychiatry (2002) 1.22
Neuroendocrine tumor recurrence: diagnosis with 68Ga-DOTATATE PET/CT. Radiology (2013) 1.22
Regional expansion of hypometabolism in Alzheimer's disease follows amyloid deposition with temporal delay. Biol Psychiatry (2011) 1.22
Longitudinal cerebral blood flow and amyloid deposition: an emerging pattern? J Nucl Med (2008) 1.22
High opiate receptor binding potential in the human lateral pain system. Neuroimage (2005) 1.20
Functional implications of hippocampal volume and diffusivity in mild cognitive impairment. Neuroimage (2005) 1.20
Brain energy metabolism and blood flow differences in healthy aging. J Cereb Blood Flow Metab (2012) 1.20
Glucose intolerance, insulin resistance, and pathological features of Alzheimer disease in the Baltimore Longitudinal Study of Aging. JAMA Neurol (2013) 1.19
Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging (2009) 1.18
Functional relevant loss of long association fibre tracts integrity in early Alzheimer's disease. Neuropsychologia (2007) 1.18
FDG-PET and CSF phospho-tau for prediction of cognitive decline in mild cognitive impairment. Psychiatry Res (2007) 1.18
PET studies of cerebral levodopa metabolism: a review of clinical findings and modeling approaches. Neuroscientist (2009) 1.16
[68Ga]-DOTATOC-PET/CT for meningioma IMRT treatment planning. Radiat Oncol (2009) 1.16
SPM-based count normalization provides excellent discrimination of mild Alzheimer's disease and amnestic mild cognitive impairment from healthy aging. Neuroimage (2008) 1.16
Association of amphetamine-induced striatal dopamine release and cortisol responses to psychological stress. Neuropsychopharmacology (2007) 1.16
Mapping neuroreceptors at work: on the definition and interpretation of binding potentials after 20 years of progress. Int Rev Neurobiol (2005) 1.15
Mechanism of new antipsychotic medications: occupancy is not just antagonism. Arch Gen Psychiatry (2003) 1.15
VMAT2 and dopamine neuron loss in a primate model of Parkinson's disease. J Neurochem (2007) 1.15
Parametric mapping of binding in human brain of D2 receptor ligands of different affinities. J Nucl Med (2005) 1.15
Dopamine release in ventral striatum during Iowa Gambling Task performance is associated with increased excitement levels in pathological gambling. Addiction (2010) 1.14
Is lactate a volume transmitter of metabolic states of the brain? Front Neuroenergetics (2012) 1.14
The thalamus as the generator and modulator of EEG alpha rhythm: a combined PET/EEG study with lorazepam challenge in humans. Neuroimage (2004) 1.14